The molecular genetics of human cancers clearly covers a very wide field. In this review therefore, I will aim to provide a broad perspective, whilst at the same time attempt to highlight those areas where remarkable advances have been made and those where they are perhaps to be expected.
I should begin by saying that there is no reason to doubt that cancer, or cancers, are very much environmentally triggered diseases, as for example we see in the association between cigarette smoking and lung cancer, but there is also no reason to doubt that cancer is also very much a genetic disease. The notion that cancers are genetic diseases goes back to the turn of the century and in particular to the work of Theodore Boveri (1914) who, on the basis of his studies on abnormalities of growth and development in sea urchins, concluded that abnormal growth resulting in cancers in animals were a direct consequence of the occurrence of chromosome abnormalities. The jump from sea urchins to mammals is in reality a small one, for, as exemplified by more recent molecular genetical studies on such diverse organisms as yeasts, round worms, fruit flies and humans, the genes that we now know are controlling elements in cellular proliferation, in differentiation, in programmed cell death (apoptosis) and organogenesis, have elements in common in all of these species. It has also been known from early studies by Paton Rous and others for example, and later by Bradford Hill and Richard Doll, that carcinogenesis is a multi-stage process which involves the occurrence of at least two and possibly as many as four or even more independent events, a realisation that has been amply confirmed by more recent molecular studies.
The common human cancers that are of major concern are cancers that involve epithelial cells such as those lining the gut, the lungs, cells in the breast and the outer surface layers of the body. These tissues comprise, and their functions are dependent on, normal proliferating cells, as indeed is the case in the bone marrow, and the emergence of a cancer is of course a consequence of a failure to control cell proliferation. The tissues I am referring to have a very high cellular turnover rate, for example our dermatologist colleagues tell us that we completely change our skins once every 6 weeks or so and there is evidence that we shed and replace some 10,000 million epithelial cells from our colons daily and that we destroy and replace some 300,000 million blood and lymphatic cells every 24 h.
The cancers that arise in these tissues are a consequence of a permanent change, or changes, resulting in an abnormally continued, or indeed enhanced, proliferative state. We can look upon these changes as being positive dominant changes driving the cell into an infinite succession of proliferative cycles; or as negative changes which result in a failure on the part of the cell to undergo a normal differentiation or a normal programmed cell death (Figure 1 ). Each of these processes of proliferation, differentiation and programmed cell death is now clearly known to be governed by a host of families of specific genes, but the first evidence of a genomic
Received and accepted 27 July 1993. mutation that was associated with a specific human malignancy dates back to the work of Peter Nowell and David Hungerford in Philadelphia in 1960 and their discovery of the so-called Philadelphia or Ph' chromosome. Nowell and Hungerford (1960) discovered the consistent presence of an altered small chromosome, the Ph' chromosome, in the malignant cells of patients with chronic myeloid leukaemia (CML), this mutation being absent in the normal cells of such patients (Figure 2 ). We now know that this small abnormal chromosome No 22 is the result of a reciprocal translocation of a terminal part of chromosome 9 onto the end of chromosome 22 and the transfer of a slightly smaller terminal region of chromosome 22 onto chromosome 9 (Figure 3 ).
The 9/22 translocation in CML involves a breakage at the 5' end of a specific gene, the abl oncogene, on chromosome 9 and the transference of that gene to a breakage site at a gene called the bcr (breakage cluster region) gene on chromosome 22. The normal product of the abl gene is a 145 kd protein which has tyrosine kinase activity and is expressed in proliferating cells where it is involved in metabolic pathways leading to proliferation. The abl gene was originally identified as the direct counterpart of the oncogenic transforming gene of the acutely transforming Ableson leukaemia retrovirus, a virus that produces leukaemia in mice. During its evolution the virus picked up this gene from a mammal and incorporated it into its own genome. The viral form of the gene, v-abl, is strongly oncogenic in mice, but the normal form of the abl gene in humans, a proto-or p-oncogene is a gene that is essential for normal cellular activity. The translocation in CML results in a mutated cellular oncogene (c-oncogene) which is an extended gene that is transcribed into a 210 kd protein. It has recently been shown that sequences within the first exon of the ber gene are essential for the oncogene activity of the fusion protein and that this gene has serine/ threonine kinase activity and can phosphorylate several different protein substrates (Maru & Witte, 1991 Figure 1 The pathway from stem cells through proliferation to differentiation and apoptosis. Br. J. Cancer (1993 ), 68, 1051 -1060 Figure 2 Lymphocyte metaphase and karyotype from a chromosome.
therefore that both the abl gene and the bcr gene may be involved in a number of intra-cellular signalling pathways and the upshot of the translocation that brings these two genes into juxtaposition is that there is a greatly enhanced tyrosine kinase activity relative to that observed in normal cells, which then serves to drive these cells containing the translocation into continued proliferation.
An abnormal abl gene is found in all CML cells, but a Ph' chromosome is also found in the malignant cells in around 10% of patients with ALL. Here the translocation is at a slightly different site resulting in a somewhat different fusion protein with a molecular weight of 190 kd, again having abnormal tyrosine kinase activity and being strongly autophosphorylated. The fact that the abl fusion protein acts in a dominant oncogenic fashion has been underlined by the work of Heisterkamp and colleagues (1990) One other recent finding of genetic interest in relation to the bcr/abl translocation is that in 11 cases where the parental origin of the two involved chromosomes could be unambiguously ascertained, in all instances the chromosome 9 (abi gene) involved the paternally derived chromosome and the chromosome 22 (bcr gene) the maternally derived homologue (Haas et al., 1992) . This entirely non-random involvement is also evident in relation to certain inherited tumour predispositions and is a phenomenon of considerable current interest that is associated with inherited genomic imprinting.
Since the discovery of the bcr/abl gene, a series of examples of translocations resulting in the formation of chimaeric genes which are activated to an oncogenic status have been described and representatives of these are listed in (Blackwood & Eisenman, 1991; Ayer et al., 1993) . The important fact is that the myc gene turns on a series of genes that are involved in the proliferation process, so that myc is turned on in proliferating cells and turned off in quiescent cells.
A second translocation of particular interest is that found in around 85% of follicular B-cell lymphomas and involves (Kerr et al., 1972) which is characterised by endonuclease mediated DNA fragmentation and chromosome condensation and depends upon RNA and protein synthesis in the dying cell (Wyllie, 1993) . It is therefore an active cell-destruct process that is a consequence of the cell's genetic constitution and its reaction to the environment. It transpires, however, that the bc12 protein actively prevents cell death and in the presence of an activated myc oncogene results in the continuous proliferation on the part of the B cells (Vaux et al., 1988) . The activated bc12 gene therefore acts as an oncogene and indeed the insertion of a bc12/Ig construct into a transgenic mouse results in extending B cell survival in the living animal and in the formation of follicular lymphomas (Adams & Corey, 1992) . This gene therefore exerts its effects through promoting clonal expansion by inhibiting cell death in a population of cells that is normally destined to die (Sentman et al., 1991; Strasser et al., 1991) . The effect of the active bcl gene in preventing programmed cell death is evident not only in lymphoid cells, but also in other cell types such as fibroblasts. Studies by Evan et al. (1992) and Bissonnette et al. (1992) have shown that if c-myc is turned on in cultured fibroblasts in the presence of growth factors and in the presence or absence of bc12, the cells undergo continual proliferation in culture. Similar proliferation is observed if c-myc and bc/2 are turned on but growth factors are absent. However, in the absence of growth factors and bc12 the cells undergo an apoptosis. Now I have deliberately introduced the findings on activation of genes to what is essentially a dominant oncogenic state as a result of chromosome translocation using the lymphoid cells as a model, since these cells are readily amenable to chromosome study and enable us to pinpoint the sites of mutation by cytogenetic means. However, I must emphasise that the first isolation and characterisation of cellular oncogenes was from solid tumours such as, for example, the Harvey-ras oncogene from human bladder carcinoma cells (Parada et al., 1982; Der et al., 1982) . Since these original studies there have been a large number of demonstrations utilising in vitro cell transformation assays to isolate a variety of proto-oncogenes that have mutated to a transforming c-oncogenic form in various cell types. These studies have identified various families of genes which are involved as growth factors, growth factor receptors, second messengers and transcription factors, all of which are involved in the processes leading to cellular proliferation (Table III) . As a result of a great deal of work now on yeast cells and on mammalian cells in culture, we have also now identified a whole range of genes involved in the mitotic process (Murray, 1992) . These genes are under the control of other genes and it is a mutation, or epigenetic change, in these controlling oncogenic genes, following exposure to carcinogenic agents, that are the important initiating factors in carcinogenesis. These studies also serve to underline the fact that in order to produce a malignant transformation it is necessary to have mutations or alterations in expression of more than one gene. As indicated earlier the carcinogenic process requires more than one independent genetic, or epigenetic, event.
So far I have spent my time talking essentially about genes whose altered expression acts in a dominant fashion in driving cells through a continued proliferative state. There are, however, other genes, so-called tumour suppressor or antioncogenes, which have the reverse effect, namely to prevent cells proceeding through a proliferative cycle and it has increasingly become evident that these genes play a very important role in carcinogenesis.
The first direct evidence that there were such genes as tumour suppressor genes came from early studies by Henry Harris and colleagues such as Harold Klinger and Eric Stanbridge who showed that the tumorigenicity, in mice, of a neoplastic human cell with an activated oncogene could be suppressed if the neoplastic cell was fused to a normal cell. The fact that such hybrid cells do not give rise to tumours shows that the action of the active oncogene is suppressed by one or more introduced normal genes. Now in such hybrid cells there is usually a loss of donor chromosomes as cells are maintained in culture, so that the cell, or rather its descen- (Francke, 1983) .
These general features of retinoblastoma are entirely in line with an hypothesis put forward by Alfred Knudson about 20 years ago that in an inherited RB a mutational event is present in, and is. transmitted by, the germ line, so that the mutation is present in all the derived somatic cells of the individual. A second mutation then occurs at the same locus in the homologous chromosome in the retinoblast and this results in a recessive change in the RB locus and the development of a tumour. This second mutation may well be, and often is, a complete loss of the chromosome bearing the wild type allele. In sporadic RB both mutations will be somatic acquired mutations. Knudson's hypothesis has been amply confirmed (Cavenee et al., 1983) and the RB gene has now been cloned and characterised (Friend et al., 1986; Lee et al., 1987) . It is a very interesting gene whose product is cyclically phosphorylated through the action of cyclins (Hinds et al., 1992) and can be shown to act as a negative controller of cellular proliferation. It is in an unphosphorylated form in GO/GI and becomes phosphorylated in the S-phase of the cell cycle (Buchkovich et al., 1989) . In its unphosphorylated form it binds to one of the proteins involved in cycling the cells into mitosis, the E2F transcription factor (Chellappan et al., 1991 ). This transcription factor activates genes involved in DNA synthesis such as DHFR, TK and the DNA a polymerase and the sequestering of E2F by pRb prevents entry into S (Nevins, 1992) . The absence of Rb, or presence in an abnormal form, thus prevents it from exerting its downregulating effect on the cell cycle. Rb has also been implicated as interacting along the pathway involving c-myc and also TGF-,I and ,2 in proliferating cells and with myo-D in the differentiation of muscle cells (Kim et al., 1992; Gu et al., 1992 Killary et al. (1992) Multiple endocrine Pancreas, llq(cent) + Larsson et al. (1988) (Seizinger, 1993) .
The p53 gene is probably the most commonly mutated gene in all sporadic cancers, it is the subject of intense world-wide study. The p53 gene codes for a 393 amino-acid phosphoprotein that is located in the cell nucleus and is normally expressed at low levels and has a short half life. It is a transcription factor with a sequence specific DNA binding region and a transactivation domain and appears to function as a regulator of genes whose products suppress cell proliferation. As with pRb, p53 is also complexed in the cell by the transforming proteins of the oncogenic DNA viruses. The wild type form of the protein acts as a tumour suppressor as for example the transfection of the wild type gene into human osteosarcoma cells lacking endogenous p53 completely abrogates the neoplasticity of the cells (Chen et al., 1990 ). Many of the mutant p53 proteins, however, act as dominant oncogenes so that co-transfection of embryo fibroblasts with c-myc and many of the mutant p53s results in transformation whereas co-transfection with c-myc and wild type p53 may not (Lane & Benchimol, 1990; Levine et al., 1991) . A large number of different point mutations within the gene have been described and many of these are so-called strong mutations that have a dominant-negative effect -the mutant protein binding to and inactivating the wild type protein in cells heterozygous for the mutation (Milner & Medcalf, 1991) . Other point mutations are so-called weak mutations that are not themselves oncogenic in the presence of a wildtype copy of the gene.
The Li Fraumeni syndrome with its range of different tumours, sarcomas, breast, gliomas, leukaemias, etc, is associated with the inheritance of a point mutation in p53 (Figure 4 ). These mutations are almost certainly 'weak' mutations, they don't act as dominant negatives, the individuals that are heterozygous for such mutations develop normally and indeed a proportion do not develop any cancers. In the inherited cancer predisposing state therefore these genes act as recessive tumour suppressors. Indeed p53 is not an essential modulator of normal cellular proliferation, for transgenic mice homozygous for knock-out of p53 develop normally and are viable, but are very prone to a wide range of tumours (Donehower et al., 1992) . Current belief is that the role of the wild-type protein is to act as a cell cycle G1-S checkpoint monitor, preventing cells from proceeding through a cell cycle following exposure to stress and DNA damaging agents, to allow DNA repair to proceed and main- taining genomic stability (Lane, 1992; Vogelstein & Kinzler, 1992) . There is also recent evidence that the down regulatory role of the gene may also be involved in the process of apoptosis (Clarke et al., 1993; Lowe et al., 1993) . Individuals heterozygous for a mutated familial adenomatous polyposis coli gene, the APC gene (Kinzler et al., 1991; Joslyn et al., 1991) , are characterised by the development of hundreds, or carpets of thousands, of colorectal adenomas some of which develop into frank carcinomas. In tumours from these patients the wild type allele on the normal chromsome is lost or mutated so that the normal gene appears to act as a tumour suppressor gene and indeed transfection of a normal chromosome 5 into cultured neoplastic colorectal cells reverses their neoplasticity. (Tanaka et al., 1991 (Powell et al., 1992) . Dr Fearon will be discussing some of this work in more detail, but I should remind you that these studies have characterised a series of somatic mutations that are causal factors in the emergence of colon cancer ( Figure 5 ), including of course the ubiquitous p53, k-ras, MCC and a suppressor gene (DCC) on chromosome 18 (Fearon et al., 1990 ).
Now it is well known that there are familial colon cancers which are not associated with the inheritance of the rare trait for adenomatous polyps-so called Hereditary Non Polyposis Coli Cancer families (Lynch et al., 1985) . Our own studies in Edinburgh confirm and extend these findings (Cohen et al., 1993) 
Concluding comments
I have attempted to cover a very wide field for it is evident that cancers are a consequence of genetic or epigenetic alterations in a variety of genes that are fundamental to the processes of growth, cell proliferation, differentiation and programmed cell removal. In my survey I have deliberately omitted discussing some interesting and relevant genetic phenomena such as DNA repair genes, imprinting and methylation, and I could have spent more time discussing the flood of knowledge that is emerging from the use of transgenic animals to investigate the target genes to which the transcription factors which are often mutated in cancer are addressed, as well as the roles played by oncogenes and suppressor genes in normal development. I hope it is evident from what I have managed to say, however, that our knowledge of the processes involved in carcinogenesis is expanding rapidly and we would do well to ask where is this knowledge leading us and how can we apply it for prevention, presymptomatic diagnosis, diagnosis and therapy?
In the fields of cancer prevention and presymptomatic diagnosis, the isolation of genes that predispose to the development of familial cancers is really a major step forward, and particularly so in the case of the more common cancers such as breast cancer. We still need to know, however, what are the risks associated with the inheritance of a mutated predisposing gene, and be able to screen those at risk and advise or treat accordingly. Genetic clinics specifically targetted at breast cancer are being set up around the country and this is going to result in the practical application of some of our basic knowledge on breast cancer to the benefit of those at high risk. Our knowledge is also going to raise a number of very important ethical and social questions and we shall have to proceed with care. We shall also hear from others at this meeting of the use of oncogene probes to detect occult early colon cancer by examining exfoliated colon cells in faeces and of the use of DNA probes for staging disease. But what of therapy?
The identification of specific oncogenes and tumour suppressor genes and their roles played in oncogenesis provides us with possible new approaches and new targets for therapy. Here there is intense interest in following various approaches and I very broadly classify them into two overlapping areas.
First the 'immunological area'. This includes approaches involving the use of humanised antibodies, the use of fusion protein vaccines, and antibody directed enzyme prodrug therapies (ADEPT), or virus directed enzyme prodrug therapy (VDEPT). Of particular interest has been approaches to modulate the immune response of the animal host or human patient by introducing genes for cytokines, such as tumour necrosis factor or IL-2, into cancer cells or into tumour infiltrating lymphocytes and reintroducing these into the body to stimulate a cytotoxic immune response against the tumour. A recent interesting development in this area has been the introduction of immunogenic neoplastic cells expressing antisense growth factor RNA (Trojan et al., 1993) . Much interest has also recently centred on the introduction of gene coding for a ligand known as B7, a surface molecule which interacts with the surface molecules (CD28) of cytotoxic T cells and acts in a costimulatory manner to activate these killer lymphocytes. Recent studies with B7 on murine melanoma have been extremely impressive (Townsend & Allison, 1993) , but whether this approach can be transferred to the clinic has yet to be established.
The second area is effectively 'gene targeting and gene therapy'. The sort of targets that are being discussed here include the ber/abl fusion gene, p53 and the bc12 gene. The turning off of a gene that prevents apoptosis has obvious attractions. The approach being followed is to use synthesised short oligonucleotides, 15-25 bases long, that are complementary to the sequence of a segment of the DNA of a gene or to its RNA message. Such anti-sense molecules which bind to DNA result in triplex structures and block transcription, similarly antisense RNA blocks translation, so that the relevant protein is no longer produced. This antisense approach has been shown to work on tumour cells in culture and although encouraging results have recently been reported in in vivo studies on rodents (Simons, et al., 1992) there is a long way to go yet before it can be shown that this approach can be effective for example in patients with resistant non-Hodgkin's lymphoma. Similarly, approaches using peptides to block oncogene products, e.g. ras p21, are being talked of, but they are a very long way from being a practical proposition.
In conclusion I think we can say that we've learnt a great deal about our genes and how they are aberrant or misbehave in carcinogenesis, the challenge now is to put this information to best use in the prevention and treatment of human cancer. ROULEAU, G., AURIAS, A. & THOMAS, G. (1992) . Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature, 359, [162] [163] [164] [165] . DER, C.J., KRONTIRIS, T.C. & COOPER, G.M. (1982) 
